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Introduction
Studies of the immune response to late-stage cancers includ-
ing the role of tumor-infiltrating CD8+ cytotoxic T lymphocytes 
(CTLs) in attacking cancer cells have led to promising new cancer 
immunotherapeutics with proven efficacy against melanoma and 
other metastatic cancers (1). However, the efficacy of immuno-
therapeutic approaches for the treatment of early-stage cancers is 
uncertain (2). This is particularly relevant to carcinomas, because 
these cancers frequently lack a significant antitumor immune 
infiltrate, especially during the early in situ phases of their devel-
opment (3). The current cancer immunotherapies like immune 
checkpoint blockade, which rely on a preexisting CTL infiltrate in 
the tumor for their effects, have relatively low efficiency against 
the early nonimmunogenic carcinomas (2, 4). In order to expand 
the potential of cancer immunotherapy, it is essential to find path-
ways that lead to immune system activation against early phases 
of cancer development. Therefore, devising a mechanism to acti-
vate the immune system against early-stage cancers has clear ther-
apeutic implications, both by directly blocking cancer promotion 
and potentiating the effects of the available cancer immunothera-
peutics against the late disease.
To substantiate the possibility of immunotherapy for early 
cancers, we have studied thymic stromal lymphopoietin (TSLP), 
which is emerging as an important cytokine in cancer immunol-
ogy (5). TSLP is an epithelium-derived cytokine that is a master 
regulator of allergic inflammation at barrier organs like the skin 
and lungs (6). We and others have previously demonstrated that 
epidermis-derived TSLP creates robust antitumor immunity in the 
skin by activating CD4+ T cells against early stages of skin cancer 
development (7–9). Interestingly, TSLP is expressed by mouse 
and human mammary gland epithelia and breast cancer cells (10), 
which raises the possibility that this cytokine may also play a role 
during the early stages of breast cancer development. Importantly, 
skin-derived TSLP, which can be induced by the FDA-approved 
topical medication calcipotriol (11, 12), can reach high systemic lev-
els and activate the immune response in internal organs (13, 14). 
In addition, epidemiological data suggest that individuals with a 
history of allergic diseases like atopic dermatitis and asthma have a 
reduced risk of developing breast cancer (15–17), which may poten-
tially be explained by elevated circulating TSLP levels in these indi-
viduals (18). Thus, an intriguing possibility with clear therapeutic 
implications is that systemic TSLP can induce antitumor immunity 
against early stages of breast cancer development.
To test the hypothesis that TSLP is active in preventing breast 
cancer, we studied the impact of TSLP expressed in the skin on 
breast tumor promotion in a murine model of spontaneous breast 
carcinogenesis. We demonstrate that TSLP blocks breast cancer 
development through activation of Th2 cells that heavily infiltrate 
the breast tumors. Interestingly, we discovered that TSLP released 
by breast tumor cells themselves functions to prevent breast 
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We found that K14-TSLPtg PyMttg mice had a significantly longer 
latency to breast tumor development (Figure 2A; P < 0.001, log-
rank test). In addition, the number of palpable breast tumors in 
each K14-TSLPtg PyMttg animal was significantly reduced com-
pared with that observed in PyMttg mice (Figure 2B; P < 0.05, start-
ing at 10 weeks of age, Student’s t test). Most notably, the lifespan 
of K14-TSLPtg PyMttg animals was not affected by their breast can-
cer burden after 150 days, a point at which all PyMttg mice had suc-
cumbed to their cancer (Figure 2C; P < 0.001, log-rank test). This 
stark contrast in survival rates between the 2 groups was due to the 
significantly smaller number of breast tumors in the K14-TSLPtg 
PyMttg mice, and these tumors remained small adenoma-like pre-
cancers that lacked metastatic potential (Figure 2D and Supple-
mental Figure 3). Thus, the K14-TSLPtg PyMttg mice were greatly 
protected from breast cancer.
Antitumor effect of TSLP is associated with a Th2-dominant 
immune response at the site of developing breast tumors. To exam-
ine the possibility that TSLP-mediated breast cancer suppression 
was caused by underdeveloped mammary glands or by a lack of 
cancer initiation in K14-TSLPtg PyMttg mice, we stained the whole 
mount of mammary glands and tumors from adult WT, K14- 
TSLPtg, PyMttg, and K14-TSLPtg PyMttg female mice with carmine 
stain to visualize the extent of mammary gland branching and the 
status of the tumors in the PyMt transgene–positive cohorts (21). 
Importantly, TSLP overexpression from the skin had no impact on 
the development of female mammary glands and their branching 
after puberty (Figure 3A). In addition, the presence of multiple 
dilated foci along the mammary ducts in K14-TSLPtg PyMttg breast 
(Figure 3A) clearly demonstrates that TSLP does not affect the 
initiation phase of breast carcinogenesis, but instead effectively 
blocks its promotion.
The suppressive effects of TSLP in blocking breast cancer 
promotion could possibly be mediated through the activation of 
antitumor immunity in the breast. To investigate this possibility, 
we characterized the immune environment in breast glands and 
tumors from age-matched WT, K14-TSLPtg, PyMttg, and K14- 
TSLPtg PyMttg female mice at the time when PyMttg mice had 
developed metastatic breast cancers (Figure 3). WT and K14- 
TSLPtg breast glands had no immune infiltrate around the mam-
mary ducts (Figure 3B), similar to that seen at earlier time points 
(Figure 1). At the later stage, PyMttg breast cancers were composed 
of densely packed collections of breast cancer cells with scattered 
T cells within them; however, K14-TSLPtg PyMttg breast tumors 
contained a dense CD4+ T cell infiltrate in close proximity to 
dilated mammary ducts in the tumor (Figure 3B). Quantification 
of the tumor-infiltrating T cells demonstrated that the majority of 
tumor-infiltrating T cells in PyMttg breast tumors were CD8+ CTLs, 
but CD4+ T cells were the dominant T cell type in K14-TSLPtg 
PyMttg breast tumors (Figure 3C). The accumulation of CD4+ T 
cells in K14-TSLPtg PyMttg breast tumors occurred in the presence 
of high serum TSLP levels during the development of breast can-
cer in these animals (Figure 3, C and D). Importantly, CD4+ T cells 
infiltrating the K14-TSLPtg PyMttg breast tumors did not express 
cytotoxic factors like granzyme B or FasL; however, their accumu-
lation in K14-TSLPtg PyMttg breast tumors was accompanied by a 
significant reduction in the expression of the tumor-promoting 
factors IL-6 (22) and IL-8 (23) within the tumor microenvironment 
tumor promotion. In addition, we show that induction of TSLP 
mounts a similar antitumor immune response against pancreatic 
cancer development. Collectively, these data establish a funda-
mental role for immune activation in combating the early stages 
of carcinogenesis and identify the mechanism for TSLP-mediated 
antitumor immunity against breast cancer.
Results
TSLP overexpression in the skin leads to T cell accumulation at the 
site of developing breast cancer. In order to determine the impact of 
systemic TSLP on the early stages of breast cancer development, 
we studied MMTV-polyoma middle T (PyMttg) mice, a well-estab-
lished spontaneous model of breast cancer that mimics luminal 
breast cancer in humans (19). We crossed this breast cancer–prone 
strain with mice that overexpress TSLP in their skin (K14-TSLPtg) 
(20). K14-TSLPtg animals develop allergic inflammation in their 
skin, which mimics atopic dermatitis in humans (13). To deter-
mine the site of TSLP expression in the animals relevant to our 
current studies, we assessed Tslp mRNA expression in the skin and 
breast glands of WT, K14-TSLPtg, and K14-TSLPtg Tslpr–/– mice, 
which lack TSLP-induced allergic inflammation. We detected 
Tslp transgene expression in the skin, but not in the breast glands 
(Supplemental Figure 1, A and B; supplemental material available 
online with this article; doi:10.1172/JCI83724DS1). Importantly, 
we demonstrated that Tslp overexpression in the skin led to high 
serum TSLP levels in K14-TSLPtg and K14-TSLPtg PyMttg animals 
(Supplemental Figure 1C). Therefore, K14-TSLPtg PyMttg ani-
mals could be used to investigate the impact of systemic TSLP on 
breast cancer development.
Analysis of the inflammatory phenotypes in K14-TSLPtg PyMttg 
animals demonstrated the development of atopic dermatitis in the 
skin at 10 weeks of age, which was highlighted by epidermal thick-
ening and dermal inflammatory infiltrate including CD4+ T cells 
(Figure 1A and Supplemental Figure 2). We also observed an accu-
mulation of mast cells in the dermis of K14-TSLPtg and K14-TSLPtg 
PyMttg animals (Figure 1A; P < 0.05, Student’s t test) (20). Similar 
to K14-TSLPtg mice (13, 14), K14-TSLPtg PyMttg animals underwent 
atopic march and developed allergic inflammation at other barrier 
sites, as shown by the accumulation of T cell–rich inflammatory 
infiltrates around the lung airways (Figure 1B). Interestingly and 
in stark contrast to K14-TSLPtg mice lacking inflammation in their 
breast, 10-week-old K14-TSLPtg PyMttg mice showed a significant 
accumulation of CD4+ T cells surrounding their dilated mammary 
glands (Figure 1C). No CD4+ T cell infiltrate was detectable in early 
breast tumors of 10-week-old PyMttg animals (Figure 1C). Nota-
bly, the early breast tumors developing in 10-week-old K14-TSLPtg 
PyMttg animals mostly presented as dilated mammary ducts and 
lacked the epithelial hyperplasia seen in PyMttg breast ductal walls 
(Figure 1C). These findings suggest that TSLP stimulates a robust 
immune response in the breast primarily in the context of a devel-
oping tumor, which prevents the tumor from progressing into fully 
formed carcinoma at the primary site.
TSLP induction blocks breast carcinogenesis in the adenoma-like 
stage. To determine the effects of systemic TSLP on breast cancer 
outcomes, we monitored spontaneous breast cancer develop-
ment in K14-TSLPtg PyMttg mice with allergic inflammation and 
compared it with their PyMttg littermates over time (Figure 2). 
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marked increase in CD4+ T and CD8+ T lymphocytes with effec-
tor and memory phenotypes in K14-TSLPtg PyMttg mice compared 
with that seen in PyMttg mice (Supplemental Figure 5). Interest-
ingly, only CD4+ T cells in K14-TSLPtg PyMttg lymph nodes showed 
increased expression of an activation marker, PD-1 (Supplemental 
(Supplemental Figure 4). Thus, systemic TSLP induction blocks 
breast cancer promotion and is associated with a large number of 
CD4+ T cells infiltrating the developing breast cancer.
Detailed analysis of the immune cells in tumor-draining 
lymph nodes of PyMttg and K14-TSLPtg PyMttg animals showed a 
Figure 1. TSLP overexpression in the skin leads to allergic inflammation in barrier organs and induces a CD4+ T cell–mediated immune response to the 
developing breast tumors. (A) TSLP expression in the skin causes atopic dermatitis–like inflammation. Representative images of H&E and toluidine blue 
staining (highlighting mast cells in purple) of skin from 10-week-old WT, K14-TSLPtg, PyMttg, and K14-TSLPtg PyMttg mice are shown. The average number 
of mast cells in 10 random high-power fields (hpf) is shown as a bar graph at the left edge of the images (*P < 0.05 compared with WT, Student’s t test). 
(B) Elevated systemic TSLP levels caused inflammation in the lungs. Representative images of H&E and CD3 staining (marking T cells) of lungs from 
10-week-old WT, K14-TSLPtg, PyMttg, and K14-TSLPtg PyMttg mice. Arrows point to the foci of inflammation around lung airways. Higher-magnification rep-
resentative images of CD3-stained lung airways are shown. Bar graphs at the left edge of the CD3-stained images show the average number of lymphocyte 
aggregate foci per lung section in 10 random lungs from each cohort (*P < 0.05 compared with WT, Student’s t test). (C) TSLP induction led to accumula-
tion of CD4+ T cells at the site of breast cancer development and to its arrest. Representative images of H&E, CD3 immunohistochemical, CD4, CD3, and 
cytokeratin (CK) immunofluorescence staining of breast glands and early tumors from 10-week-old WT, K14-TSLPtg, PyMttg, and K14-TSLPtg PyMttg mice. 
The average number of tumor-infiltrating CD4+ T cells in 10 random hpf is shown as a bar graph at the left edge of the immunofluorescence images  
(*P < 0.05 compared with WT, Student’s t test). Data were reproduced in 3 independent experiments. Scale bars: 100 μm.
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and refs. 25, 26). These findings firmly establish Th2 cells as the 
dominant adaptive immune cells associated with TSLP-induced 
antitumor immunity in the breast.
T cells mediate TSLP-induced antitumor immunity in the breast. 
To determine whether T cells are required for TSLP-mediated 
antitumor immunity in the breast, we performed weekly Ab-based 
CD4+ and CD8+ T cell depletion in PyMttg and K14-TSLPtg PyMttg 
animals starting in their second week of life, before the animals 
reached puberty (Figure 5). Injection of animals with anti-CD4 
and anti-CD8 Abs for up to 15 weeks led to complete depletion of 
CD4+ and CD8+ T cells in the circulation (Supplemental Figure 
10). Interestingly, there was complete resolution of skin inflam-
mation in the K14-TSLPtg PyMttg animals, as shown by the nor-
malization of hair coat, epidermal thickness, cellular density, and 
mast cell counts in the dermis (Figure 5A and Supplemental Fig-
ure 10). Although depletion of T cells did not affect the kinetics 
of breast cancer development in PyMttg animals (27), sustained T 
cell depletion resulted in a clear loss of breast cancer resistance 
in K14-TSLPtg PyMttg animals (Figure 5). K14-TSLPtg PyMttg ani-
mals treated with anti-CD4 and anti-CD8 Abs developed multi-
ple invasive breast cancers with tumor latency similar to that in 
PyMttg mice. Moreover, there were tumor metastases to the lungs 
and survival was compromised (Figure 5, B–D, and Supplemental 
Figure 11). To test whether CD4+ Th2 cells specifically mediated 
the antitumor effects of TSLP in the K14-TSLPtg PyMttg breast, 
we attempted to deplete only CD4+ or CD8+ T cells in K14-TSLPtg 
PyMttg animals following the same protocol as above. Although 
Figure 5). CD4+ T cells stained for the GATA3 and FOXP3 tran-
scription factors identified the expanded population of CD4+ 
T cells in K14-TSLPtg PyMttg lymph nodes as being GATA3+ Th2 
cells, while FOXP3+ Tregs were the dominant CD4+ T cell type in 
the PyMttg immune microenvironment (Supplemental Figure 5). 
Consistent with these findings, the expression of type 2 cytokines 
like Il4 was significantly upregulated, whereas expression of type 1 
cytokines such as Ifng and Tnf was significantly downregulated in 
K14-TSLPtg PyMttg lymph nodes compared with that detected in 
PyMttg lymph nodes (Figure 4A; P < 0.05, Student’s t test). TSLP 
induction did not induce the expression of Il33, another epithelium- 
derived cytokine implicated in allergic inflammation (Figure 4A, 
Supplemental Figure 6, and ref. 24). Importantly, immunopheno-
typing of the tumor-infiltrating T cells identified the majority of 
these cells as CD4+ Th2 effector cells in K14-TSLPtg PyMttg breast 
tumors, because the CD4+ T cells expressed GATA3 and lacked 
T-bet or FOXP3 expression (Figure 4B). Despite the significant 
Th2 cell infiltration into the K14-TSLPtg PyMttg breast tumors, 
systemic TSLP did not result in the accumulation of mast cells 
or basophils within the K14-TSLPtg PyMttg tumors (Supplemental 
Figure 7). Finally, MHCII (I-Ab) staining of breast tumors from 
K14-TSLPtg PyMttg mice generated on a pure C57BL/6 background 
(H2b) showed the presence of MHC class II+ antigen-presenting 
cells (APCs) in close contact with breast tumor cells and T cells 
within K14-TSLPtg PyMttg breast tumors (Supplemental Figure 8). 
CD11b+CD11c+ conventional DCs constituted the majority of the 
MHC class II+ APCs in the breast tumors (Supplemental Figure 9 
Figure 2. TSLP blocks breast cancer development. (A–C) K14-TSLPtg PyMttg female mice were protected from breast cancer compared with their PyMttg 
counterparts. Graphs show (A) the time to tumor onset, (B) the average number of breast tumors per mouse, and (C) the animals’ rate of survival (n ≥14 in 
each group; *P < 0.05 starting at week 10, Student’s t test; **P < 0.001, log-rank test). (D) K14-TSLPtg PyMttg female mice had atopic dermatitis–like skin 
rashes but smaller adenomatous breast tumors and no lung metastasis compared with PyMttg mice. Representative images of H&E-stained breast cancer 
and lung tissue from K14-TSLPtg PyMttg and PyMttg female mice. Scale bars: 1 cm (mouse), 1 mm (histology).
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FVB genetic background, K14-TSLPtg PyMttg mice on the C57BL/6 
genetic background were resistant to breast cancer development, 
and this resistance was completely reversed in K14-TSLPtg PyMttg 
Tslpr–/– mice, which were prone to developing breast cancer to 
a degree similar to that seen in PyMttg animals (Supplemental 
Figure 13). To establish an experimental system that allowed for 
a predictable tumor promotion time frame and controlled out-
come measurements, we orthotopically implanted primary breast 
tumor cells from PyMttg mice into the inguinal mammary fat 
pads of WT and K14-TSLPtg recipients (Supplemental Figure 14). 
Breast tumors grew significantly larger in WT animals compared 
with that observed in their K14-TSLPtg counterparts, in which the 
tumors were mostly arrested as small nodules that had dilated 
breast ducts within them (Supplemental Figure 14; P < 0.05, Stu-
dent’s t test). This result confirms that TSLP blocks the promotion 
of an implanted primary breast tumor, which is identical to its 
effects on a spontaneously forming breast tumor.
Next, we investigated the role of CD4+ T cells in TSLP-medi-
ated immunity against breast cancer (Figure 6A). Primary breast 
anti-CD8 Ab depletion alone led to an effective depletion of CD8+ 
T cells in K14-TSLPtg PyMttg blood, anti-CD4 Ab alone failed to 
deplete CD4+ T cells, probably due to the TSLP stimulatory pres-
sure on these cells (Supplemental Figure 12). Notably, and despite 
the effective CD8+ T cell depletion, anti-CD8 Abs failed to alter the 
allergic skin inflammation in the K14-TSLPtg PyMttg animals (Sup-
plemental Figure 12, A and B). These findings demonstrate that 
T cells play an essential role in mediating the antitumor immune 
response mounted by TSLP in the breast and that CD4+ Th2 cells 
are the likely T cell type required for this effect.
TSLP-stimulated Th2 cells are responsible for blocking breast 
cancer promotion. We established the tumor-protective effects of 
systemic TSLP against breast cancer using mice on a tumor-prone 
FVB genetic background. In order to show similar effects in a dif-
ferent genetic background and provide the foundation for a more 
detailed study of the role of CD4+ T cells in TSLP-mediated tumor 
immunity, we studied K14-TSLPtg PyMttg and K14-TSLPtg PyMttg 
Tslpr–/– animals generated on a pure C57BL/6 genetic background 
(Supplemental Figure 13). Similar to the corresponding mice on the 
Figure 3. TSLP-induced breast cancer suppression is associated with accumulation of CD4+ T cells around the arrested breast tumor foci. (A) Breast 
gland development in K14-TSLPtg PyMttg female mice was intact, but the breast cancer promotion phase was inhibited in these animals. Representative 
images of carmine-stained (mammary ducts in red) breast glands and tumors from age-matched WT, K14-TSLPtg, PyMttg, and K14-TSLPtg PyMttg female 
mice when PyMttg animals had developed palpable tumors. (B) Endpoint histological analysis revealed CD4+ T cell infiltrate surrounding dilated mam-
mary ducts in K14-TSLPtg PyMttg female mice. Representative images show H&E, CD4/CD3/CK, and CD8/CD3/CK immunofluorecence staining of adjacent 
sections of breast glands and tumors. Note that the tissues were from age-matched WT, K14-TSLPtg, PyMttg, and K14-TSLPtg PyMttg female mice when the 
PyMttg animals had developed terminal metastatic breast cancers. (C) The majority of T cells in K14-TSLPtg PyMttg tumors were CD4+ T cells. Bar graphs 
show the average number of tumor-infiltrating CD4+ and CD8+ T cells in 10 random hpf within the glands and tumors of WT, K14-TSLPtg, PyMttg, and 
K14-TSLPtg PyMttg mice (*P < 0.05 compared with PyMttg, Student’s t test). (D) At the terminal stage of cancer in PyMttg mice, circulating TSLP levels rose 
in PyMttg mice, but remained significantly higher in K14-TSLPtg and K14-TSLPtg PyMttg animals. Bar graph shows the serum TSLP levels in WT, K14-TSLPtg, 
PyMttg, and K14-TSLPtg PyMttg female mice when the PyMttg animals had reached the metastatic breast cancer endpoint (n = 4 per group; *P < 0.05 com-
pared with WT, Student’s t test). Data were reproduced in 3 independent experiments. Scale bars: 100 μm.
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tumors were isolated from PyMttg Tslpr–/– animals, which lack the 
TSLP receptor on all their cells, including the immune cells that 
might have been left behind, even after CD45+ cell depletion of 
the tumor. These tumors were transferred to K14-TSLPtg Tslpr–/– 
female mice, which, prior to tumor implantation, had received 
Tslpr–/– or congenically marked WT CD4+ T cells from naive 
mice (Figure 6A). Interestingly, the breast tumors that formed in 
inguinal mammary fat pads of the recipient K14-TSLPtg Tslpr–/– 
mice were significantly smaller in the mice receiving WT CD4+ 
T cells than in those receiving Tslpr–/– CD4+ T cells (Figure 6B; 
P < 0.05, Student’s t test). A similar result was obtained when the 
tumor cells were injected into thoracic mammary fat pads (Sup-
plemental Figure 15). Remarkably, the majority of the tumor- 
infiltrating WT CD4+ T cells that rendered recipient K14-TSLPtg 
Tslpr–/– mice resistant to breast tumors became GATA3+ Th2 cells 
and showed a higher degree of proliferation compared with the 
Tslpr–/– CD4+ T cells present in the tumor (Figure 6C). Collectively, 
these data provide strong evidence that Th2 cells stimulated by 
TSLP are at the heart of the antitumor immunity against breast 
cancer development, while also indicating that the breast tumor 
cells themselves are not responding to TSLP.
Topical induction of TSLP blocks breast tumor growth in a Th2 
cell–dependent manner. We hypothesized that the induction of 
TSLP at the time of breast cancer development provides the poten-
tial to be an effective immunotherapeutic approach for breast can-
cer treatment. To test this hypothesis, we used an FDA-approved 
topical medication, calcipotriol, which is a known inducer of TSLP 
in the skin (11). We administered 20 nmol calcipotriol or EtOH 
carrier onto the ears of age-matched WT and Tslpr–/– female mice 
every 3 days, starting immediately before adoptive transfer of con-
genically marked WT CD4+ T cells and implantation of primary 
PyMttg Tslpr–/– breast tumor cells into their right inguinal mammary 
fat pad (Figure 7A). Topical application of calcipotriol onto the ani-
mals’ ears led to a significant increase in circulating TSLP levels 
(Figure 7B, P < 0.05, Student’s t test). WT animals that received 
calcipotriol developed significantly smaller tumors compared with 
EtOH-treated WT controls (Figure 7, C and D, P < 0.05, Student’s t 
test). Interestingly, Tslpr–/– mice treated with EtOH developed sig-
nificantly larger tumors than did EtOH-treated WT controls (Fig-
ure 7, C and D, P < 0.05, Student’s t test). This finding demonstrates 
that endogenous TSLP released by the breast cancer cells (Supple-
mental Figure 16) acts to suppress breast cancer growth (Figure 7, C 
and D). Tslpr–/– mice treated with calcipotriol showed tumor growth 
kinetics similar to that seen in EtOH-treated Tslpr–/– mice, demon-
strating that the calcipotriol effect on breast cancer suppression is 
mediated through TSLP (Figure 7, C and D). Importantly, Tslpr–/– 
mice that received both WT CD4+ T cells and calcipotriol gained 
a robust resistance to breast tumor growth, highlighting the obser-
vation that CD4+ T cells directly responded to TSLP signal and 
mounted an antitumor immune response in the breast (Figure 7, C 
and D, P < 0.05, Student’s t test).
To further investigate the nature of the CD4+ T cells respon-
sible for antitumor immunity in the breast in response to topical 
calcipotriol treatment, we determined their transcription factor 
expression pattern. As shown in a genetic model of TSLP induc-
tion, WT mice treated with calcipotriol showed expansion of 
GATA3+ Th2 cells in their growth-arrested tumors (Figure 7E). 
Notably, WT CD4+ T cells that were transferred into calcipotriol- 
treated Tslpr–/– mice and responsible for mounting the TSLP- 
induced antitumor immune response became GATA3+ Th2 cells 
(Figure 7E). Evaluation of ears, back skin, and lungs in the cal-
cipotriol-treated animals showed localized inflammation in the 
Figure 4. TSLP induces the accumulation of CD4+ T cells and their polarization to Th2 cells in breast tumors and their draining lymph nodes. (A) Cyto-
kine profiling of the tumor-draining lymph nodes revealed that the Th2-polarized cytokine milieu dominated in K14-TSLPtg PyMttg animals. Bar graphs 
show the relative mRNA expression of several Th1- and Th2-related cytokines versus Gapdh in K14-TSLPtg PyMttg tumor–draining lymph nodes compared 
with PyMttg tumor–draining lymph nodes (n = 4 per group; *P < 0.05 compared with PyMttg, Student’s t test). (B) Th2 cells formed the dominant type 
of T cells infiltrating the K14-TSLPtg PyMttg breast tumors. Representative flow cytometric plots show the percentage of CD4+ and CD8+ T cells in PyMttg 
and K14-TSLPtg PyMttg breast tumors. T-bet, GATA3, and FOXP3 transcription factor staining delineated the characteristics of the tumor-infiltrating CD4+ 
T cells in PyMttg and K14-TSLPtg PyMttg animals. Flow cytometric data were reproduced in 6 independent experiments. Data were collected when PyMttg 
animals had reached the metastatic breast cancer endpoint. Numbers in the flow cytometric plots represent the percentage of the plotted cell population. 
Bar graph demonstrates the percentage of Th1 and Th2 cells and Tregs within the PyMttg and K14-TSLPtg PyMttg breast tumors (n ≥4 per group; *P < 0.05 
compared with PyMttg, Student’s t test).
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ears, but no sign of systemic allergic inflammation at the barrier 
organs in response to the short-term induction of TSLP through 
topical calcipotriol treatment (Supplemental Figure 17). Together, 
these findings demonstrate the tumor-suppressive effects of 
endogenous TSLP expressed by a developing breast cancer and 
substantiate the potential of TSLP induction to yield an effective 
immunotherapeutic for breast cancer treatment with minimal 
systemic side effects.
TSLP induction blocks tumor growth in late-stage breast can-
cer. We have demonstrated that systemic induction of TSLP 
and local TSLP expression by breast cancer cells act to suppress 
breast cancer development. In contrast to our findings, previous 
studies showed that endogenous TSLP released from breast can-
cer cell lines is protumorigenic (10, 28). To test the effects of sys-
temic TSLP induction on a breast cancer cell line, we generated 
a cell line from PyMttg breast tumors (Supplemental Figure 18A). 
Consistent with previous findings (10, 28), WT animals injected 
with the PyMttg tumor cell line developed significantly larger 
tumors compared with Tslpr–/– recipients (Supplemental Figure 
18; P < 0.05, Student’s t test). The reason for the opposite effect of 
endogenous TSLP on tumor cell lines is unclear, but it should be 
noted that breast cancer cell line–derived tumors are poorly differ-
entiated and have lost epithelial characteristics such as cytokeratin 
expression, similar to a late-stage metastatic cancer (Supplemen-
tal Figure 19). Nonetheless, we found that tumor cell line growth 
was still suppressed in K14-TSLPtg animals (Supplemental Figure 
18; P < 0.05 compared with WT, Student’s t test). Notably, CD4+ T 
cells, which were largely GATA3+ Th2 polarized, constituted the 
majority of tumor-infiltrating lymphocytes in K14-TSLPtg mice 
compared with WT and Tslpr–/– animals (Supplemental Figure 18; 
P < 0.05, Student’s t test). Thus, TSLP expressed locally by breast 
tumor cells can be coopted by tumor-derived cell lines to promote 
the growth of the breast tumor cells, but TSLP induction can still 
block their growth by recruiting Th2 cells to the tumor, consis-
tent with our findings of the tumor-suppressive effect of TSLP on 
developing primary tumors.
TSLP induction blocks pancreatic tumor growth. In order to 
determine the extent of the TSLP tumor–suppressive effects in 
blocking early cancer development, we examined the role of TSLP 
in pancreatic cancer, which is a prime example of a cancer with 
minimal baseline immunity (3). A previous study has suggested 
that endogenous TSLP released by pancreatic cancer–associated 
fibroblasts is protumorigenic in metastatic pancreatic cancer (29). 
Therefore, elucidating the role of TSLP in early-stage pancreatic 
Figure 5. T cells are required for TSLP-induced antitumor immunity in the breast. (A) CD4+ and CD8+ T cell depletion starting in the second week of life 
abrogated the atopic dermatitis–like skin inflammation in K14-TSLPtg PyMttg mice. Representative images are shown of H&E- and toluidine blue–stained 
skin from adult PyMttg and K14-TSLPtg PyMttg mice. The animals were analyzed when the control Ab–treated PyMttg mice had developed terminal disease. 
The average number of mast cells in 10 random hpf is shown as a bar graph in the left edge of the images (*P < 0.05 compared with PyMttg treated with 
control Ab, Student’s t test). Scale bars: 100 μm. (B–D) K14-TSLPtg PyMttg female mice treated with anti-CD4 and anti-CD8 Abs (CD4/8 Ab) lost their 
resistance against breast cancer development. Graphs show (B) the time to tumor onset, (C) the average number of breast tumors per mouse, and (D) the 
survival percentage for anti-CD4–, anti-CD8–, and control Ab–treated PyMttg and K14-TSLPtg PyMttg mice (n = 6 in each group). *P < 0.05, log-rank test  
(B and D); *P < 0.05 starting at week 12 compared with PyMttg treated with control Ab, Student’s t test (C).
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that systemic TSLP induction against primary pancreatic tumors 
leads to their growth suppression, accompanied by a significant 
accumulation of Th2 cells within the tumor microenvironment.
Discussion
The main impact of this report is the demonstration that an anti-
tumor immune response can be effectively induced against early 
stages of cancer development. The ability to activate the immune 
system to attack a developing cancer highlights a novel aspect of 
cancer immunology with great potential to produce robust and 
durable treatments against cancer. This approach can yield cancer 
immunopreventive measures that will eliminate carcinoma in situ, 
cancer has major implications for our understanding of TSLP’s 
function in cancer. To test the effect of TSLP induction on pan-
creatic cancer development, we isolated spontaneous pancreatic 
tumors from P48+/Cre LSL-KRASG12D p53fl/+ animals (30). These 
primary tumors were transferred into WT and K14-TSLPtg mice 
to monitor their growth in the presence of systemic TSLP. Inter-
estingly, pancreatic tumors formed in K14-TSLPtg mice were sig-
nificantly smaller than those formed in WT mice (Figure 8, A and 
B; P < 0.05, Student’s t test). Importantly, there was a significant 
increase in the number of GATA3+ Th2 cells infiltrating K14-TSLPtg 
tumors compared with that seen in their WT counterparts (Figure 
8, C and D; P < 0.05, Student’s t test). These findings demonstrate 
Figure 6. TSLP blocks breast cancer promotion through 
stimulation of Th2 cells. (A) Schematic diagram depicting the 
experimental paradigm used to test the role of CD4+ T cells in 
TSLP-mediated immunity against breast cancer. Six- to eight-
week-old K14-TSLPtg Tslpr–/– animals received WT or Tslpr–/– 
CD4+ T cells and were implanted 2 days later with PyMttg 
Tslpr–/– primary breast tumors. WT CD4+ T cells were congen-
ically marked (CD45.1+). (B) WT CD4+ T cells were sufficient to 
receive TSLP signal and mount an antitumor immune response 
in the breast. Representative images are shown of K14-TSLPtg 
Tslpr–/– mice with their implanted tumors. Red arrow points 
to a small tumor in the K14-TSLPtg Tslpr–/– animal injected 
with WT CD4+ T cells. Shown are H&E-stained tumor sections 
isolated from K14-TSLPtg Tslpr–/– animals that received WT or 
Tslpr–/– CD4+ T cells. Inset highlights an area of the tumor that 
shows reversion to a dilated gland structure in a small tumor 
that formed in the K14-TSLPtg Tslpr–/– mouse injected with WT 
CD4+ T cells. Scatter plot shows the average volume of the 
breast tumors forming in each K14-TSLPtg Tslpr–/– mouse that 
received WT or Tslpr–/– CD4+ T cells at the time point when the 
tumors of the Tslpr–/– T cell–injected animals had reached their 
terminal volume (n = 8 in each group; *P < 0.05, Student’s t 
test). Scale bars: 1 cm (mouse), 500 μm (histology). (C) WT 
CD4+ T cells isolated from growth-arrested breast tumors of 
K14-TSLPtg Tslpr–/– mice were polarized to Th2 cells and showed 
increased proliferation. Representative flow cytometric plots 
show the FOXP3 and GATA3 expression status of tumor- 
infiltrating CD4+ T cells in K14-TSLPtg Tslpr–/– mice that received 
WT or Tslpr–/– CD4+ T cells. Congenically marked (CD45.1+) WT 
CD4+ T cells are highlighted in red. Numbers in the flow plots 
represent the percentage of cells within each box. Histograms 
show the percentage of Ki67+CD4+ T cells.
Downloaded from http://www.jci.org on May  1, 2016.   http://dx.doi.org/10.1172/JCI83724
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
1 4 6 6 jci.org   Volume 126   Number 4   April 2016
Figure 7. Topical TSLP induction blocks 
breast cancer development. (A) Sche-
matic diagram outlining the experimental 
design used to test the efficacy of topical 
calcipotriol treatment in blocking breast 
cancer development. Six- to eight-week-
old WT and Tslpr–/– animals were used 
as tumor recipients. The animals were 
treated with 20 nmol calcipotriol or EtOH 
on their ears every 3 days, starting before 
adoptive T cell transfer (in a subgroup of 
Tslpr–/– animals) and PyMttg Tslpr–/– pri-
mary breast tumor implantation. (B) Top-
ical calcipotriol treatment on ears led to 
elevated TSLP levels in the circulation. Bar 
graph shows the average levels of TSLP 
in the serum of WT mice treated with 
calcipotriol or EtOH (*P < 0.05, Student’s 
t test). (C and D) TSLP induction by cal-
cipotriol blocked breast tumor growth in a 
TSLP- and CD4+ T cell–dependent manner. 
Endogenous TSLP expressed by breast 
tumor cells also acted to suppress breast 
tumor growth. (C) Graph demonstrates 
the average tumor volumes in 5 cohorts of 
mice tested (n = 6 in each group; *P < 0.05 
compared with the WT plus EtOH group, 
Student’s t test). (D) Representative 
images of the implanted primary breast 
tumors are shown (red arrow points to 
small tumors). Scale bar: 1 cm. (E) CD4+  
T cells in calcipotriol-treated WT mice and 
WT CD4+ T cells transferred into calcipotri-
ol-treated Tslpr–/– mice were polarized to 
Th2 cells. Representative flow cytometric 
plots of tumor-infiltrating CD4+ T cells 
in recipient mice are shown (numbers in 
each box represent the percentage of CD4+ 
T cells). Congenically marked (CD45.1+) 
WT CD4+ T cells are highlighted in red. 
Bar graph shows the percentage of Th1 
and Th2 cells and Tregs within the breast 
tumors in each group (n = 6 per group;  
*P < 0.05 compared with the WT plus 
EtOH group, Student’s t test). The data 
were reproduced in 3 independent  
experiments.
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of the antitumor immune response in the breast, which signifies 
the previously unrecognized efficacy of this immune cell type in 
suppressing cancer development.
Although the tumor-protective effects of atopy against skin 
cancer have been previously described (7–9, 32), this study pro-
vides clear evidence for a similar effect against an internal cancer 
with metastatic potential. TSLP is a master regulator of atopic dis-
eases in barrier organs like the skin and lungs (33). In response to 
barrier disruption, TSLP is expressed by epithelial cells that are 
attempting to repair the barrier and alert the immune system of 
the breach. However, in the face of chronic barrier defects, con-
tinuous TSLP overexpression leads to the development of atopic 
dermatitis and asthma in the skin and lungs, respectively (33). Pre-
vious reports demonstrated that TSLP-induced allergic inflamma-
tion in the skin protected it from cancer (7–9); however, it was not 
clear whether this protection would extend to cancers in nonbar-
rier sites. We believe our current findings conclusively demon-
strate that systemic TSLP released by the skin mounts an effective 
antitumor immune response specifically at the site of a developing 
cancer in the breast and does not cause inflammation in a breast 
free of initiated cancer cells. Therefore, a barrier organ site for the 
tumor and preexisting allergic inflammation are not required for 
TSLP-mediated tumor immunity.
As TSLP is increased in the blood of patients with atopic dis-
eases (18), our results provide an explanation for the reduced rate 
of cancer in these patients reported in epidemiological studies 
(15–17). In addition, our calcipotriol studies demonstrate that a 
short-term induction of systemic TSLP leads to antitumor immu-
nity at the sites of breast cancer development, without general-
ized allergic inflammation as side effects. Hence, the systemic 
approach to TSLP induction may provide a safe and effective 
prevent the development of late-stage metastatic cancers, and 
result in the recruitment of a much broader repertoire of immune 
effector cells against early and late cancers.
Here, we demonstrate that TSLP-stimulated CD4+ Th2 cells 
are the key mediators of the antitumor immune response that 
blocks early stages of breast cancer development, protecting ani-
mals from advanced breast cancer and metastasis. Importantly, 
we found that a similar TSLP-induced immunity blocked the 
growth of primary pancreatic tumors. These findings identify sev-
eral fundamental concepts that can advance our understanding of 
immune system interactions with cancer. First, our data suggest 
that, in addition to CD8+ CTLs, which are the prime immune cell 
type studied in cancer immunology (1), CD4+ Th cells are impor-
tant players in antitumor immunity, especially in early cancers. 
This finding suggests that CD8+ CTLs found in late-stage cancers 
may have been initially recruited by CD4+ Th cells responding to 
the cancer at its earlier stages of development, similar to the ini-
tiating role that CD4+ T cells play in other inflammatory condi-
tions like autoimmune diabetes (31). Next, this work emphasizes 
the importance of actively stimulating CD4+ Th cells against early 
stages of solid cancers like breast cancer, in which baseline anti-
tumor immunity is minimal (3). Through this approach, tumor- 
infiltrating CD4+ T cells, which are the upstream activators of the 
immune response, can mediate potent anticancer effects. The 
CD4+ T cells appeared not to be cytotoxic themselves and did not 
express tumor-promoting factors; rather, they recruited a broad 
repertoire of immune effector cells to attack the cancer more 
effectively. However, the observed effects appear to be indepen-
dent of mast cells or basophils, since they were found in low den-
sities and were not expanded upon TSLP exposure in the breast 
cancer lesions. Thus, Th2-polarized lymphocytes are at the heart 
Figure 8. TSLP suppresses primary pancreatic 
tumor growth. (A) Graph shows the average volume 
of P48+/Cre LSL-KRASG12D p53fl/+ pancreatic tumors 
transferred into WT and K14-TSLPtg mice over time. 
(B) Representative images show tumors 30 days 
after implantation of primary pancreatic tumor 
cells into the right flank of 6- to 8-week-old WT and 
K14-TSLPtg mice. Scale bar: 1 cm. (C) Bar graph shows 
the percentage of T-bet+ Th1 cells, GATA3+ Th2 cells, 
and FOXP3+ Tregs in the pancreatic tumors formed 
in WT and K14-TSLPtg animals. (D) Representative 
flow cytometric plots demonstrate FOXP3, GATA3, 
and T-bet expression in tumor-infiltrating CD4+ T 
cells in recipient mice. The data were reproduced in 2 
independent experiments (n = 6 in each group;  
*P < 0.05 compared with WT, Student’s t test). 
Detailed experimental procedures are available in the 
Supplemental material.
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engage the CD4+ T cells to attack the cancer. More specifically, the 
efficacy of topical calcipotriol in inhibiting breast cancer growth in 
a TSLP- and Th2 cell–dependent manner provides an exciting pos-
sibility for the use of this FDA-approved medication in the treat-
ment of early breast cancer lesions, especially those that are not 
cured by surgical excision alone.
Methods
Mice. Mice carrying both K14-TSLPtg (a gift of Andrew Farr, Univer-
sity of Washington, Seattle, Washington, USA) and PyMttg transgenes 
were generated by crossing PyMttg mice on an FVB background with 
K14-TSLPtg mice on a mixed background. These K14-TSLPtg PyMttg 
mice were maintained on an FVB background. For experiments using 
mice on the C57BL/6 background, PyMttg mice generated directly 
on a C57BL/6 background were crossed with K14-TSLPtg Tslpr–/– mice 
(Tslpr–/– mice were a gift of Warren Leonard, NIH, Bethesda, Maryland, 
USA) that were also generated directly on a C57BL/6 background. All 
mice included in the breast cancer experiments were monitored daily 
for tumor onset and growth. For all breast cancer experiments, the mice 
were sacrificed if their tumor exceeded 2 cm in diameter or the animals 
showed any sign of distress or weight loss. In cancer survival experi-
ments, we harvested one K14-TSLPtg PyMttg animal, together with any 
of its end-stage cancer–bearing PyMttg littermates, in order to perform 
our tissue and immune cell analyses on the test and control mice at the 
same age; hence, some of the K14-TSLPtg PyMttg animals that were oth-
erwise healthy exited the survival analysis at the time of euthanasia.
Ab depletion. K14-TSLPtg PyMttg and PyMttg mice received an i.p. 
injection of 750 μg anti-CD4 (GK1.5) and/or anti-CD8 (YTS169.4) or 
control Ab (anti-rat IgG; Sigma-Aldrich) in the second week of life. 
The animals continued to receive 250 μg depleting Abs weekly. Anti-
CD4 and anti-CD8 Abs were produced by the Protein Production and 
Purification Facility of the Rheumatic Diseases Core Center (RDCC) 
at Washington University.
Primary breast tumor transfer and calcipotriol treatment studies. Pri-
mary breast tumor cells were obtained from PyMttg or PyMttg Tslpr–/– 
donor mice. Primary tumors in the donor animals were harvested 
before the tumors reached 2 cm in diameter. Donor mice were injected 
with 50 μl heparin, followed by anesthetics and whole-body perfusion 
with 30 ml PBS under sterile conditions. Approximately 3 to 4 grams 
of whole tumor was then meshed through a 70-μm filter into a lysing 
solution consisting of RPMI (Sigma-Aldrich), Liberase TL (170 μg/
ml; Roche), and DNase I (30 μg/ml; Roche) in a 6-well plate. A breast 
tumor single-cell suspension and small pieces were transferred into a 
50-ml tube and placed in a shaker at 37°C for 2 hours at 225 rpm. A 
breast tumor single-cell suspension was then meshed through a new 
70-μm filter into a fresh 50-ml tube. Breast tumor cells were resus-
pended in 2 ml MACS buffer (0.5% BSA and 2 mM EDTA in PBS), fol-
lowed by 100 μl CD45+ microbeads for 30 minutes on ice (Miltenyi 
Biotec). Primary breast tumor cells were isolated away from CD45+ 
leukocytes using CD45+ microbeads and magnetic columns according 
to the manufacturer’s protocol (Miltenyi Biotec). Primary breast tumor 
cells were resuspended at a concentration of 2 × 106 cells per 200 μl 
RPMI (Sigma-Aldrich). Cells (2 × 106/mouse) were injected into the 
animals’ right inguinal mammary fat pad (ninth mammary gland) on 
day 0 (D0). For adoptive T cell transfer experiments, CD4+ T cells 
were injected 2 days before tumor implantation. In topical calcipotriol 
treatment experiments, the mice were divided into 2 groups and were 
immunotherapy to direct the antitumor immunity specifically to 
the site of the primary cancer and its micrometastasis.
Importantly, we found that in breast cancer–derived cell lines, 
the endogenous TSLP signal is coopted by the cancer cells to pro-
mote their growth, as shown in previous studies (10, 28). This pro-
tumorigenic effect of TSLP on breast cancer cell lines is mediated 
through OX40L+ DCs (10) and may involve a collection of immune 
cells like the M2 macrophages present in a type 2 inflammatory 
microenvironment (34). Interestingly, systemic TSLP overexpres-
sion can still stimulate the specific expansion of CD4+ T cells in the 
cell line–derived breast tumor and block its growth. Collectively, 
these results emphasize the importance of TSLP as a potent anti-
tumor immune signal that can be deployed to achieve an effective 
immunity against early- and late-stage breast cancer.
An important and direct implication of TSLP induction for 
breast cancer immunotherapy relates to the treatment of lobular 
and ductal carcinoma in situ (LCIS and DCIS). These localized 
breast lesions have high rates of recurrence, even after surgical 
excision (35, 36). More important, the presence of a subset of 
these precancerous lesions is a marker for increased risk of cancer 
in both breasts (35, 36). Importantly and consistent with our find-
ings in animal models, a clinical study recently found that TSLP 
expression in early-stage breast cancers correlates with improved 
outcomes (37). Therefore, TSLP induction can prove to be an 
effective cancer immunotherapeutic against these early breast 
cancer lesions by directing the adaptive immunity to sites of exist-
ing but subclinical cancers and preventing new lesions from devel-
oping over time through the immune memory response.
TSLP establishes its tumor immunity against breast cancer 
by stimulating CD4+ T cells to infiltrate the breast cancer as acti-
vated and/or memory Th2 cells. Although we have shown that 
TSLP-stimulated CD4+ T cells accumulate in close proximity to 
MHCII+ APCs that have also infiltrated the tumor under TSLP 
pressure, the exact nature of the antigens that are detected by 
these T cells remains to be elucidated in future studies. Also, the 
effector mechanism of the TSLP-stimulated Th2 cells that effec-
tively blocks breast cancer development remains a topic for future 
research. We did not find that the tumor-infiltrating CD4+ T cells 
express granzymes, perforin, or Fas ligand, which would give rise 
to cytotoxic potential. Therefore, other adaptive immune cells 
like B cells (32) and CD8+ CTLs, as well as innate immune cells 
and/or stromal components of the tumor, are likely playing an 
effector role downstream of the CD4+ T cells to execute the anti-
tumor effects observed.
In summary, this work describes previously unrecognized 
effects of TSLP and Th2 cells in blocking breast carcinogenesis 
that can be extended to other cancers, such as pancreatic cancer. 
TSLP overexpression in the skin establishes a potent antitumor 
immunity in the breast through direct stimulation of CD4+ Th2 
cells. Likewise, endogenous TSLP released by breast cancer cells 
suppresses the growth of the cancer, which is later used by breast 
cancer–derived cell lines to promote their own growth. Together, 
these findings demonstrate the importance of studying cancer 
immunology in the context of a developing spontaneous cancer in 
order to determine the full breadth of immune system interactions 
with cancer. This study has clear therapeutic implications for the 
treatment of early and late cancers by providing a mechanism to 
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treated with either calcipotriol (20 nmol) or ethanol as a carrier on 
their ears starting 2 days before CD4+ T cell transfer. Calcipotriol or 
ethanol treatments were continued every 3 days.
Breast cancer cell line studies. The PyMttg cancer cell line was gen-
erated from a mammary tumor from a 6-month-old PyMttg mouse on 
a C57BL/6 background. Tumor cells were grown on collagen-coated 
plates in 10% FBS plus DMEM and passaged 10 times before use. The 
cell line was screened for vimentin and EpCAM to verify its epithe-
lial nature. Cells were screened for mouse Ab production (MAP) and 
mycoplasma. Cells were passaged at 70% confluency, and 4 × 105 
breast cancer cells were injected into the lateral inguinal mammary fat 
pad (ninth mammary gland) on D0.
Statistics. All statistical analyses for tumor onset and survival were 
performed using the log-rank test to determine significant differences 
between study groups in 2-way comparisons with the control group. A 
2-tailed Student’s t test was used to determine significance between 
tumor counts, tumor volumes, mRNA expression, TSLP serum levels, 
and all other measurements in 2-way comparisons with the control 
group. A P value of less than 0.05 was considered significant, and all 
error bars represent SD.
Study approval. All mice were maintained in pathogen-free facili-
ties according to guidelines instituted by the animal study committees 
of Washington University and Massachusetts General Hospital. All 
animal studies were reviewed and approved by the IACUCs of Wash-
ington University and Massachusetts General Hospital.
Refer to the Supplemental Methods for further description of the 
experimental procedures.
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